79440-34-9

Basic information

• Product Name: 6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine
• Synonyms: 6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine
• CAS NO: 79440-34-9
• Molecular Formula: C₉H₉BrO₂
• Molecular Weight: 229.07056
• Mol File: 79440-34-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 291.2±19.0 °C(Predicted)
• Appearance: /
• Density: 1.549±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine(79440-34-9)
• EPA Substance Registry System: 6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine(79440-34-9)

Safety Data

• Hazard Codes: Xi,N
• Statements: 36-51/53
• Safety Statements: 26-60-61
• Hazardous Substances Data: 79440-34-9(Hazardous Substances Data)

Usage

General Description

6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine is a chemical compound with the molecular formula C9H9BrO2. It is a type of dioxane compound that contains a bromomethyl group and is a close derivative of benzodioxane. This chemical compound is primarily used in organic synthesis and pharmaceutical research as a building block for the preparation of various biologically active substances and pharmaceutical drugs. Its unique structure and reactivity make it a valuable intermediate in the production of a wide range of organic compounds with potential applications in medicinal chemistry, agrochemicals, and materials science. Due to its potential biological activity, 6-(bromomethyl)-2,3-dihydrobenzo[b][1,4]dioxine is also of interest in the field of drug discovery and development.

Upstream product

• 39270-39-8 (2,3-dihydro-benzo[1,4]dioxin-6-yl)-methanol 
• 4442-54-0 2,3-dihydro-1,4-benzodioxin-6-carboxylic acid 
• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 

Downstream Products

• 169045-07-2 2-{[4-chloro-3-(methyloxy)phenyl]methyl}-1H-isoindole-1,3(2H)-dione 
• 247570-06-5 N-(3,4-ethylenedioxybenzyl)phthalimide 
• 1239355-12-4 2-{[2-chloro-4-(trifluoromethyl)phenyl]oxy}-N-[(1R)-1-{[(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)oxy]methyl}-2-(4-methylpiperazin-1-yl)-2-oxoethyl]pyridine-3-carboxamide 
• 1400793-43-2 7-[3-(benzylideneamino)methyl-4-(3',4'-ethylenedixoybenzyloxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid 
• 247570-14-5 5-bromo-N-(4-chloro-3-methoxybenzyl)-2-fluorobenzamide 
• 247570-15-6 N-(4-chloro-3-methoxybenzyl)-2-fluoro-5-vinylbenzamide 
• 247569-43-3 N-(4-chloro-3-methoxybenzyl)-2-fluoro-5-nitrobenzamide 
• 247567-34-6 N-Benzyl-2-[2-hydroxy-1-(hydroxymethyl)ethylamino]-5-nitrobenzamide 
• 247568-34-9 2-fluoro-5-nitro-N-(1,3-benzodioxol-5-ylmethyl)benzamide 

Relevant articles and documents

INHIBITORS FOR THE Β-CATENIN / T-CELL FACTOR PROTEIN–PROTEIN INTERACTION

Disclosed are inhibitors for the β-catenin/T-cell factor interaction. The inhibitors are selective for β-catenin/T-cell factor over β-catenin/cadherin and β-catenin/APC interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

Synthesis and in vitro antibacterial activity of gemifloxacin derivatives containing a substituted benzyloxime moiety

A series of novel gemifloxacin (GMFX) derivatives containing a substituted benzyloxime moiety with remarkable improvement in lipophilicity were synthesized. The target compounds evaluated for their in vitro antibacterial activity against representative strains. Our results reveal that most of the target compounds have considerable potency against all of the tested Gram-positive strains including MRSA and MRSE (MIC: 90: 1 μg/mL) is 8-fold more active than GMFX, and 2-fold more active than GMFX and moxifloxacin against MRSE clinical isolates (MIC90: 4 μg/mL). Crown Copyright

Evaluation of quinazoline analogues as glucocerebrosidase inhibitors with chaperone activity

Gaucher disease is a lysosomal storage disorder (LSD) caused by deficiency in the enzyme glucocerebrosidase (GC). Small molecule chaperones of protein folding and translocation have been proposed as a promising therapeutic approach to this LSD. Most small molecule chaperones described in the literature contain an iminosugar scaffold. Here we present the discovery and evaluation of a new series of GC inhibitors with a quinazoline core. We demonstrate that this series can improve the translocation of GC to the lysosome in patient-derived cells. To optimize this chemical series, systematic synthetic modifications were performed and the SAR was evaluated and compared using three different readouts of compound activity: enzymatic inhibition, enzyme thermostabilization, and lysosomal translocation of GC.